Virology

The AstraZeneca/Oxford University Phase 3 COVID-19 Vaccine Trial €“ Why Was It Paused?

by Helen Stillwell Recently, a Phase 3 trial investigating a COVID-19 vaccine (AZD1222) being developed by AstraZeneca and the University of Oxford was put on hold in the US following a report of an adverse event in a study participant in the U.K. (Feuerstein 2020). One of the predominant vaccine ...

TWiV 663: The joy of vax

Daniel Griffin provides a clinical report on COVID-19, including vaccines, Alan summarizes a vaccine webinar on the most advanced US trials, a nidovirus from snapping turtles, longevity of memory B cells in recovered patients, and listener email. The British people can face any misfortune with fortitude & buoyancy as long ...

Longevity of SARS-CoV-2 memory B cells

Immunity conferred by influenza virus vaccine is short-lived. After immunization with inactivated influenza virus vaccine, serum antibody levels peak within a few months and then decline rapidly. This decline was recently shown to be caused by loss of bone marrow plasma cells, a major source of serum antibodies. Results of ...

TWiV 661: SWAG with Ralph Baric

Ralph Baric returns to TWiV to provide an update on the COVID-19 resurgence in the US, monoclonal antibodies, antiviral drugs, vaccines, immunity and reinfection, reopening schools, and what will happen this fall. Click arrow to playDownload TWiV 661 (70 MB .mp3, 116 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv

TWiV 660: In case of emergency finish the trial

Daniel Griffin provides a clinical report on COVID-19, then we discuss decline of virus-specific bone marrow B cells within a year after influenza vaccination, the push to release SARS-CoV-2 vaccines before completion of phase 3 trials, and absence of evidence for infectious virus in aerosols. Click arrow to playDownload TWiV 660 ...
Scroll to Top